Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-Current Assets (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Non-Current Assets for 11 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 6983.33% to $3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.0 million, a 126.34% increase, with the full-year FY2023 number at $1.5 million, up 39.22% from a year prior.
  • Non-Current Assets was $3.7 million for Q3 2025 at Crescent Biopharma, up from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.3 million in Q1 2021 to a low of $52320.0 in Q3 2024.
  • A 5-year average of $2.4 million and a median of $2.1 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: crashed 95.61% in 2024, then skyrocketed 6983.33% in 2025.
  • Crescent Biopharma's Non-Current Assets stood at $3.6 million in 2021, then plummeted by 69.2% to $1.1 million in 2022, then skyrocketed by 39.22% to $1.5 million in 2023, then crashed by 96.57% to $52320.0 in 2024, then surged by 6983.33% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Non-Current Assets are $3.7 million (Q3 2025), $3.2 million (Q2 2025), and $52320.0 (Q3 2024).